CCM
NBIX icon

Condor Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Condor Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
6,456
+58
+0.9% +$8.61K 0.08% 121
2026
Q1 		$843K Buy
6,398
+104
+2% +$13.8K 0.07% 124
2025
Q4 		$893K Sell
6,294
-14
-0.2% -$2.03K 0.07% 127
2025
Q3 		$886K Hold
6,308
– – 0.07% 131
2025
Q2 		$793K Buy
6,308
+67
+1% +$7.68K 0.07% 133
2025
Q1 		$690K Buy
+6,241
New +$791K 0.06% 138

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Condor Capital Management's NBIX Position: Q2 2026 in Review

Condor Capital Management increased its Neurocrine Biosciences (NBIX) stake by 0.91% in Q2 2026, buying an estimated $8.61K and bringing the position to 6,456 shares worth $1.09M. The position accounts for 0.08% of the portfolio, ranked #121.

Condor Capital Management first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Condor Capital Management held 6,456 shares of Neurocrine Biosciences worth $1.09M as of Q2 2026.
  • Condor Capital Management bought 58 Neurocrine Biosciences shares in Q2 2026, an estimated $8.61K.
  • Neurocrine Biosciences made up 0.08% of Condor Capital Management's portfolio in Q2 2026, its #121 holding.
  • Condor Capital Management first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Condor Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.